Advanced Soft Tissue Sarcomas: Incorporating the Latest Advances Into Collaborative Care

Advanced Soft Tissue Sarcomas: Incorporating the Latest Advances Into Collaborative Care

Thursday, June 13, 2019 in Lawrenceville, GA
Live Meeting -- Gwinnett Medical Center, 12:00 PM ET
Building 631, Suite 220, Cancer Community Room


STS Disease Overview and General Principles

The Importance of a Multidisciplinary Team in STS Diagnosis and Treatment Planning

Advanced STS Treatment

  • Therapeutic Approach Overview
  • Selecting Among Treatment Options in the First-line and Second-line Settings
  • Evolving Topics and Ongoing Clinical Trials

Insights to Help Community Oncologists in Their Everyday Practice

  • Overall Referral Considerations
  • Best Practices in Community Oncology and Expert Center Collaboration, Referral, and Patient Transfers

Question and Answer Session


Jonathan Trent, MD, PhD

Professor of Medicine
Department of Medical Oncology
Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, Florida

Goal Statement
The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with soft tissue sarcoma (subtypes with nonspecific histologies) and establish more efficient infrastructures to support physician collaboration and timely, more prevalent referrals among community oncologists and expert sarcoma treatment centers.

Target Audience 
This program is intended for oncologists and other oncology healthcare providers who care for patients with STS.

Learning Objectives 

  • Discuss contemporary multidisciplinary strategies used in the management of advanced STS to formulate treatment plans for patients
  • Plan individualized treatment strategies based on disease characteristics as well as patient age/fitness, comorbidities, and preferences
  • Evaluate key safety and efficacy data on recently approved therapies for advanced STS in the context of evolving treatment paradigms and multimodality sequencing in multiple lines of care
  • Apply the available data, treatment guidelines, and expert recommendations to select therapy for advanced STS
  • Facilitate physician collaboration and referrals among community oncologists and sarcoma treatment centers
  • Identify patients who are eligible to enroll on ongoing clinical trials


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-518-L01-P.

Type of Activity

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.